STRATA Skin Sciences Inc., a medical technology company focused on dermatologic treatments, reported its first quarter 2025 financial results. The company achieved revenue of $6.8 million, marking a 1% increase compared to the previous year. Global net recurring XTRAC® revenue reached $4.5 million, a slight decrease from $4.6 million in the prior year period. However, this was bolstered by 27% growth in international markets, which helped offset a 4% decline in the domestic market. The company reported a net loss of $2.4 million for the first quarter of 2025, showing an improvement from a net loss of $3.4 million in the same quarter of 2024. Total operating expenses decreased by 5% to $5.7 million, with significant reductions in engineering and product development costs by 60%, selling and marketing costs by 1%, and general and administrative expenses by 5% compared to the previous year. As of March 31, 2025, STRATA Skin Sciences had cash, cash equivalents, and restricted cash totaling $7.8 million.